Table 2.
Clinical trials targeting pyroptosis to enhance ICB therapy
| NCT number | Study name | Treatment strategies | Cancer type |
|---|---|---|---|
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Biological: nivolumab Drug: cetuximab Drug: cisplatin Radiation: radiotherapy |
Ovarian cancer |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) | Biological: nivolumab Biological: ipilimumab Drug: cisplatin Drug: fluorouracil |
Various advanced cancer |
| NCT01454102 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Biological: nivolumab Drug: gemcitabine Drug: cisplatin Drug: pemetrexed Drug: paclitaxel Drug: carboplatin Drug: bevacizumab Drug: erlotinib Biological: ipilimumab |
Non-small cell lung cancer |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Biological: ipilimumab Biological: placebo matching ipilimumab Drug: etoposide Drug: cisplatin Drug: carboplatin |
Small cell lung carcinoma |
| NCT03348904 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | Drug: nivolumab Drug: epacadostat Drug: placebo Drug: carboplatin Drug: cisplatin Drug: gemcitabine Drug: paclitaxel Drug: pemetrexed |
Lung cancer |
| NCT02659059 | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV <softenter>Non-Small Cell Lung Cancer (CheckMate 568) | Biological: nivolumab Biological: ipilimumab Drug: platinum doublet chemotherapy |
Non-small cell lung cancer |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Biological: nivolumab Drug: gemcitabine Drug: cisplatin Drug: carboplatin Drug: paclitaxel Drug: pemetrexed |
Stage IV or recurrent non-small cell lung cancer |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) | Biological: ipilimumab Biological: nivolumab Drug: carboplatin Drug: paclitaxel Drug: pemetrexed Drug: cisplatin |
Non-small cell lung cancer |
| NCT02899299 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) | Biological: nivolumab Biological: ipilimumab Drug: pemetrexed Drug: cisplatin Drug: carboplatin |
Mesothelioma |
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Biological: nivolumab Drug: cetuximab Drug: cisplatin Radiation: radiotherapy |
Squamous cell carcinoma of the head and neck |
| NCT02367781 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) | Biological: atezolizumab Drug: carboplatin Drug: nab-paclitaxel Drug: pemetrexed |
Carcinoma, non-squamous non-small cell lung cancer |
| NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+ Paclitaxel+ Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150) | Biological: atezolizumab Drug: bevacizumab Drug: carboplatin Drug: paclitaxel |
Carcinoma, non-small cell lung cancer |
| NCT02578680 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | Biological: pembrolizumab Drug: cisplatin Drug: carboplatin Drug: pemetrexed Dietary supplement: folic acid Dietary supplement: vitamin b12 Drug: dexamethasone Drug: saline solution |
Non-small cell lung carcinoma |